1. Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits
- Author
-
Min Hee Ham, Se Joon Woo, Young Joo Park, Kyu Hyung Park, Hye Kyoung Hong, Simin Lee, Joo Young Son, Ki Dong Park, Jae Yong Chung, Hyeong Min Kim, and Xuanyou Jin
- Subjects
0301 basic medicine ,concentration ,intravitreal ,medicine.medical_specialty ,genetic structures ,efficacy ,Biomedical Engineering ,Angiogenesis Inhibitors ,Article ,Aqueous Humor ,Efficacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Ranibizumab ,Ophthalmology ,medicine ,Animals ,Dosing ,Adverse effect ,Retina ,business.industry ,Retinal ,eye diseases ,Vitreous Body ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Intravitreal Injections ,030221 ophthalmology & optometry ,Rabbits ,sense organs ,Intravitreal ranibizumab ,business ,pharmacokinetics ,medicine.drug - Abstract
Purpose To investigate intraocular pharmacokinetics of 10-fold dose of intravitreally injected ranibizumab compared with the conventional dose in an experimental model. Methods Ranibizumab 30 µL at 10 mg/mL (conventional) and 100 mg/mL (10-fold) doses was injected separately into each eye of 28 rabbits. Ranibizumab concentrations in the aqueous humor, vitreous, and retina were estimated at each time period after injection, using enzyme-linked immunosorbent assay. The pharmacokinetic properties of ranibizumab were determined using a one-compartment model in all three ocular tissues. The time-concentration profile and predictive trends were plotted to determine drug efficacy in the retina. Results Maximum concentrations after conventional and 10-fold dosing were observed in the retina at 1 and 4 days after injection, respectively. The half-life of ranibizumab after conventional and 10-fold dosing did not differ in the anterior chamber and vitreous, whereas the half-life was prolonged approximately twice with the 10-fold dose in the retina (36.74 h vs. 76.85 h) and serum (91.93 h vs. 179.01 h). Similarly, the estimated time for ranibizumab concentration in the retina over 27 ng/mL (minimum effective concentration of ranibizumab) was prolonged approximately twice with the 10-fold dose (1315 h [55 days] vs. 2393 h [100 days]). No adverse effects were observed in either group. Conclusions The retinal half-life and concentration of ranibizumab in rabbit eyes were increased approximately twice after a 10-fold dose compared with the conventional dose. This finding indicates a possibility to lengthen the injection interval to improve the efficacy of ranibizumab in human eyes. Translational relevance Our results highlight the potential for clinical application of a high-dose (10-fold) of anti-VEGF agents to prolong the intravitreal injection intervals, simultaneously improving the drug efficacy.
- Published
- 2020
- Full Text
- View/download PDF